Switching from MDI to iGlarLixi kept HbA1c similar and lowered weight
Punto clave:
In adults with type 2 diabetes using multiple daily injections, switching to once-daily iGlarLixi kept HbA1c about the same over 24 weeks while lowering weight, insulin dose, and some hyperglycemia measures.
Estudio de un vistazo
Qué se estudió
Switching adults with type 2 diabetes from MDI insulin to once-daily iGlarLixi
Tipo de estudio
Randomized Controlled Trials (RCTs)
duration
Medium-Term (3–12 mo)
Intervención
Insulin Glargine-Lixisenatide dosis
Resultados
HbA1c, Body weight, BMI, Daily insulin dose, Fasting Plasma Glucose, Postprandial glucose, Time in level 2 hyperglycemia, Glycemia risk index, Treatment satisfaction, Hypoglycemia events
Financiamiento
Financiado por la industria
mainEffects
HbA1c ↔ stayed similar between iGlarLixi and MDI over 24 weeks
Body weight ↓ more with iGlarLixi than with continued MDI
Total daily insulin dose ↓ substantially after switching to iGlarLixi
Marked hyperglycemia time ↓ and glycemia risk index ↓ with iGlarLixi
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Insulin Glargine-Lixisenatide dosis (Medications) |  BMI (Weight & Anthropometrics) | Decrease | Strong |
Insulin Glargine-Lixisenatide dosis (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Strong |
Insulin Glargine-Lixisenatide dosis (Medications) |  Daily insulin dose (Glycemic Control) | Decrease | Strong |
Insulin Glargine-Lixisenatide dosis (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Limited |
Insulin Glargine-Lixisenatide dosis (Medications) | Glycemia risk index (Glycemic Control) | Decrease | Strong |
Insulin Glargine-Lixisenatide dosis (Medications) | HbA1c (Glycemic Control) | Uncertain | Limited |
Insulin Glargine-Lixisenatide dosis (Medications) |  Hypoglycemia events (Safety) | Decrease | Mixed |
Insulin Glargine-Lixisenatide dosis (Medications) | Postprandial glucose (Glycemic Control) | Uncertain | Limited |
Insulin Glargine-Lixisenatide dosis (Medications) | Time in level 2 hyperglycemia (Glycemic Control) | Decrease | Strong |
Insulin Glargine-Lixisenatide dosis (Medications) |  Treatment satisfaction (Patient-Reported) | Increase | Mixed |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- The between-group difference in HbA1c change was -0.12%, which suggests similar overall glycemic control.
- Body weight fell 4.19 kg more with iGlarLixi than with continued MDI.
- Total daily insulin dose changed by -28.57 IU in favor of iGlarLixi.
- Time spent above 13.9 mmol/L and glycemia risk index both improved more with iGlarLixi.
Who this applies to
These results apply most directly to adults with type 2 diabetes who were already using multiple daily insulin injections, had preserved fasting C-peptide, and were treated in specialist diabetes care. The average participant was older, had long-standing diabetes, and had obesity or overweight.
Keep in Mind
This study tested treatment simplification in a selected group, not in everyone with type 2 diabetes on insulin. The main glycemic outcome was similar between groups, so the benefit came more from lower treatment burden, lower insulin dose, weight loss, and some sensor-based glucose measures. Because the trial was open label and modest in size, the findings are best used as supportive rather than definitive for all patients.
Between the Lines
- The study was open label, so patient-reported outcomes were more vulnerable to bias.
- Only 90 participants were analyzed.
- The trial was conducted in one country and all participants were white.
- Most participants were men, which limits how broadly the findings may apply.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Referencia de la Revista
Novodvorsky P, Thieme L, Lankova I, et al. Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial. Diabetes Obes Metab. 2026;28(3):1817-1825. doi:10.1111/dom.70362
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Supporting Evidence
Supporting evidence and related resources.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.